Species Dependent Esterase Activities for Hydrolysis of an Anti-HIV Prodrug Glycovir and Bioavailability of Active SC-48334

Overview

Journal Pharm Res

Specialties Pharmacology
Pharmacy

Date 1995 Aug 1

PMID 7494828

Citations 7

Authors

C S Cook

P J Karabatsos

G L Schoenhard

A Karim

Affiliations

Soon will be listed here.

Abstract

Purpose: The in vitro fate of an ester prodrug, glycovir, was studied to determine if the species differences in the bioavailability of pharmacologically active SC-48334 observed after glycovir administration and not observed after SC-48334 administration is due to species differences in ester hydrolysis rate or species differences in absorption of the prodrug itself, and to determine the site(s) of ester hydrolysis which contributes most to species differences in the bioavailability of SC-48334 if any.

Methods: Glycovir was incubated with small intestinal mucosa, liver S9 fractions, whole blood, red blood cells (RBC) and plasma of the rat, dog, monkey (cynomolgus and rhesus) and man, and glycovir concentrations were determined by HPLC.

Results: The relative bioavailabilities of SC-48334 after prodrug administration to the rat, dog, monkey and man were 99, 15, 42 and 37%, respectively. After SC-48334 administration, SC-48334 was rapidly and similarly well absorbed in all species. The hydrolysis rate in the small intestinal mucosa was well correlated with the relative bioavailability of SC-48334 after prodrug administration. Among different species the hydrolysis rate of glycovir in liver S9 fractions, blood, RBC and plasma did not parallel those in the mucosa of the small intestine.

Conclusions: The species differences in bioavailability of SC-48334 with the prodrug were due to species differences in hydrolysis rates of the prodrug in small intestinal mucosa. The monkey was a good animal model for prediction of esterase activity in human small intestine and relative bioavailability in man.

Citing Articles

Lipophilic nanocrystal prodrug-release defines the extended pharmacokinetic profiles of a year-long cabotegravir.

Gautam N, McMillan J, Kumar D, Bade A, Pan Q, Kulkarni T Nat Commun. 2021; 12(1):3453.

PMID: 34103484 PMC: 8187380. DOI: 10.1038/s41467-021-23668-x.

Ester Prodrugs of IHVR-19029 with Enhanced Oral Exposure and Prevention of Gastrointestinal Glucosidase Interaction.

Ma J, Wu S, Zhang X, Guo F, Yang K, Guo J ACS Med Chem Lett. 2017; 8(2):157-162.

PMID: 28197304 PMC: 5304290. DOI: 10.1021/acsmedchemlett.6b00332.

A novel prodrug strategy to improve the oral absorption of O-desmethylvenlafaxine.

Liu M, Sun Y, Zhao S, Li Y, Piao R, Yang Y Exp Ther Med. 2016; 12(3):1611-1617.

PMID: 27588083 PMC: 4997966. DOI: 10.3892/etm.2016.3453.

Basics and recent advances in peptide and protein drug delivery.

Bruno B, Miller G, Lim C Ther Deliv. 2013; 4(11):1443-67.

PMID: 24228993 PMC: 3956587. DOI: 10.4155/tde.13.104.

Antiviral therapies targeting host ER alpha-glucosidases: current status and future directions.

Chang J, Block T, Guo J Antiviral Res. 2013; 99(3):251-60.

PMID: 23816430 PMC: 7114303. DOI: 10.1016/j.antiviral.2013.06.011.

References

Rowland M, RIEGELMAN S, Harris P, Sholkoff S . Absorption kinetics of aspirin in man following oral administration of an aqueous solution. J Pharm Sci. 1972; 61(3):379-85. DOI: 10.1002/jps.2600610312. View

Miyauchi M, Hirota T, Fujimoto K, Ide J . Studies on orally active cephalosporin esters. IV. Effect of the C-3 substituent of cephalosporin on the gastrointestinal absorption in mice. Chem Pharm Bull (Tokyo). 1989; 37(12):3272-6. DOI: 10.1248/cpb.37.3272. View

ALDRIDGE W . Serum esterases. I. Two types of esterase (A and B) hydrolysing p-nitrophenyl acetate, propionate and butyrate, and a method for their determination. Biochem J. 1953; 53(1):110-7. PMC: 1198110. DOI: 10.1042/bj0530110. View

Luttrell W, Castle M . Species differences in the hydrolysis of meperidine and its inhibition by organophosphate compounds. Fundam Appl Toxicol. 1988; 11(2):323-32. DOI: 10.1016/0272-0590(88)90157-1. View

Karpas A, Fleet G, Dwek R, PETURSSON S, Namgoong S, Ramsden N . Aminosugar derivatives as potential anti-human immunodeficiency virus agents. Proc Natl Acad Sci U S A. 1988; 85(23):9229-33. PMC: 282712. DOI: 10.1073/pnas.85.23.9229. View

Yang S, Hsieh Y, Chang W, Huang J . Enantioselectivity of microsomal and cytosolic esterases in rat intestinal mucosa. Drug Metab Dispos. 1992; 20(5):719-25. View

Quon C, Mai K, Patil G, Stampfli H . Species differences in the stereoselective hydrolysis of esmolol by blood esterases. Drug Metab Dispos. 1988; 16(3):425-8. View

Narawane M, Podder S, Bundgaard H, Lee V . Segmental differences in drug permeability, esterase activity and ketone reductase activity in the albino rabbit intestine. J Drug Target. 1993; 1(1):29-39. DOI: 10.3109/10611869308998762. View

Morikawa M, Inoue M, Tsuboi M . Substrate specificity of carboxylesterase (E.C.3.1.1.1) from several animals. Chem Pharm Bull (Tokyo). 1976; 24(7):1661-4. DOI: 10.1248/cpb.24.1661. View

10.

Cook C, Hauswald C, Oppermann J, Schoenhard G . Involvement of cytochrome P-450IIIA in metabolism of potassium canrenoate to an epoxide: mechanism of inhibition of the epoxide formation by spironolactone and its sulfur-containing metabolite. J Pharmacol Exp Ther. 1993; 266(1):1-7. View

11.

Sinkula A, Yalkowsky S . Rationale for design of biologically reversible drug derivatives: prodrugs. J Pharm Sci. 1975; 64(2):181-210. DOI: 10.1002/jps.2600640203. View

12.

Williams F . Clinical significance of esterases in man. Clin Pharmacokinet. 1985; 10(5):392-403. DOI: 10.2165/00003088-198510050-00002. View

13.

Inoue M, Morikawa M, Tsuboi M, Sugiura M . Species difference and characterization of intestinal esterase on the hydrolizing activity of ester-type drugs. Jpn J Pharmacol. 1979; 29(1):9-16. DOI: 10.1254/jjp.29.9. View

14.

Conney A . Pharmacological implications of microsomal enzyme induction. Pharmacol Rev. 1967; 19(3):317-66. View